ID   PaCaDD-60
AC   CVCL_8782
SY   PACADD-60
DR   cancercelllines; CVCL_8782
DR   Cell_Model_Passport; SIDM01375
DR   Cosmic; 1559060
DR   Wikidata; Q54937432
RX   DOI=10.4172/2324-9293.1000104;
RX   PubMed=21683373;
CC   Population: Caucasian.
CC   Doubling time: 22.19 hours (PubMed=21683373).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=21683373).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C8294; Pancreatic adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 17
//
RX   DOI=10.4172/2324-9293.1000104;
RA   Wagenhauser M.U., Ruckert F., Niedergethmann M., Grutzmann R.,
RA   Saeger H.-D.;
RT   "Distribution of characteristic mutations in native ductal
RT   adenocarcinoma of the pancreas and pancreatic cancer cell lines.";
RL   Cell Biol. Res. Ther. 2:1000104.1-1000104.5(2013).
//
RX   PubMed=21683373; DOI=10.1016/j.jss.2011.04.021;
RA   Ruckert F., Aust D., Bohme I., Werner K., Brandt A., Diamandis E.P.,
RA   Krautz C., Hering S., Saeger H.-D., Grutzmann R., Pilarsky C.;
RT   "Five primary human pancreatic adenocarcinoma cell lines established
RT   by the outgrowth method.";
RL   J. Surg. Res. 172:29-39(2012).
//